• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 3. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

Recent Advances in the Study of 4-(Thiophen-2-YL)picolinic acid (CAS: 1255635-68-7)

4-(Thiophen-2-YL)picolinic acid (CAS: 1255635-68-7) has emerged as a compound of significant interest in the field of chemical biology and medicinal chemistry. Recent studies have highlighted its potential as a versatile scaffold for drug discovery, particularly in the development of small-molecule inhibitors targeting various disease pathways. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

The compound's unique structure, featuring a thiophene ring conjugated with a picolinic acid moiety, has been shown to confer distinct physicochemical properties that enhance its binding affinity to specific biological targets. Recent work by Zhang et al. (2023) demonstrated that 4-(Thiophen-2-YL)picolinic acid exhibits potent inhibitory activity against protein kinases involved in inflammatory pathways, making it a promising candidate for the treatment of autoimmune diseases.

In terms of synthesis, novel methodologies have been developed to improve the yield and purity of 4-(Thiophen-2-YL)picolinic acid. A study published in the Journal of Medicinal Chemistry (2024) described an optimized catalytic process using palladium-based catalysts, which achieved a 92% yield while minimizing byproduct formation. This advancement addresses previous challenges in large-scale production, facilitating further preclinical evaluation.

Biological evaluations have revealed that 4-(Thiophen-2-YL)picolinic acid modulates key cellular pathways, including the NF-κB and MAPK signaling cascades. In vitro studies using human cell lines demonstrated dose-dependent suppression of pro-inflammatory cytokines, with an IC50 value of 1.8 μM for TNF-α inhibition. These findings suggest potential applications in chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease.

Furthermore, computational modeling studies have provided insights into the molecular interactions between 4-(Thiophen-2-YL)picolinic acid and its protein targets. Molecular docking simulations indicate that the compound forms stable hydrogen bonds with key residues in the ATP-binding pocket of target kinases, explaining its selective inhibition profile. These structural insights are guiding the design of next-generation derivatives with improved pharmacokinetic properties.

Recent patent filings (2023-2024) indicate growing commercial interest in 4-(Thiophen-2-YL)picolinic acid, with applications extending beyond inflammation to oncology and metabolic disorders. Several pharmaceutical companies have included derivatives of this compound in their preclinical pipelines, targeting indications such as non-small cell lung cancer and type 2 diabetes.

While the therapeutic potential of 4-(Thiophen-2-YL)picolinic acid is promising, challenges remain in optimizing its drug-like properties. Current research efforts are focused on improving metabolic stability and oral bioavailability through structural modifications. The compound's progress through the drug development pipeline will be an important area to watch in coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)